Marly E Lowery, PA-C in Birmingham, AL - Pediatrics

Marly E Lowery, PA-C is a Pediatrics based in Birmingham, Alabama. Marly E Lowery is licensed to practice in Alabama (license number 2222) and her current practice location is 1600 7th Ave S, Birmingham, Alabama. She can be reached at her office (for appointments etc.) via phone at (205) 638-9100.

NPI number for Marly E Lowery is 1306545140 and her current mailing address is 11968 Basswood Cir, Northport, Alabama. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1306545140.

Contact Information

	Marly E Lowery, PA-C
	1600 7th Ave S, Birmingham, AL 35233-1711
	(205) 638-9100
	Not Available

Provider's Profile

Full Name	Marly E Lowery
Gender	Female
Speciality	Pediatrics
Location	1600 7th Ave S, Birmingham, Alabama
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1306545140
Provider Enumeration Date: 03/01/2023
Last Update Date: 10/04/2023

Medical Identifiers

Medical identifiers for Marly E Lowery such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1306545140	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
363A00000X	Physician Assistant	(* (Not Available))	Secondary
208000000X	Pediatrics	2222 (Alabama)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Marly E Lowery is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Marly E Lowery, PA-C 11968 Basswood Cir, Northport, AL 35475-3490 Ph: (205) 765-7944	Marly E Lowery, PA-C 1600 7th Ave S, Birmingham, AL 35233-1711 Ph: (205) 638-9100

News Archive

Upsher-Smith announces FDA approval of sNDA for Qudexy XR extended-release capsules

Upsher-Smith Laboratories, Inc. announced that it has received U.S. Food and Drug Administration approval of a supplemental new drug application (sNDA) for Qudexy XR (topiramate) extended-release capsules for use as initial monotherapy in patients two years of age and older who are experiencing partial-onset seizures (POS) or primary generalized tonic-clonic seizures.

New study: Economic crisis a major barrier to U.S. life settlements market

The life settlements market was hit hard by the economic crisis and other factors in 2008, according to a new study by Conning Research and Consulting.

New glucose monitoring system from Edwards Lifesciences and Dexcom receives the CE Mark

Edwards Lifesciences Corporation, the leader in the sciences of heart valves and hemodynamic monitoring, and DexCom, Inc., a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems, today announced the receipt of CE Mark for an automatic glucose monitoring system.

Scientists discover incident commander in the brain that defends against invading virus

Imagine seeing a building on fire. You grab the phone and call the fire service. What happens next can be compared to the discovery made by researchers from Aarhus University.

Planning for first clinical trial of MERS-CoV vaccine candidate now underway

Researchers from Ludwig-Maximilians-Universitaet in Munich have demonstrated, in a preclinical setting, the protective effect of a candidate vaccine directed against the coronavirus that causes Middle East Respiratory Syndrome. Planning for the first clinical trial is now underway.

Marly E Lowery, PA-C - Pediatrics in Birmingham, AL